Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 3/20 | 0.53 |
| ▸ | MMP9 | P14780 | 3/20 | 0.53 |
| ▸ | MMP13 | P45452 | 3/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.53 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091388 | 0.91 | MMP8 (0.58) | ALDH1A1KMT2ARAPGEF3LARS1PPARG | |
| SCHEMBL3093748 | 0.91 | LARS1 (0.54) | ALDH1A1KDM4EKMT2ARAPGEF3MMP1 | |
| SCHEMBL3100450 | 0.90 | LARS1 (0.53) | ALDH1A1KDM4EKMT2ARAPGEF3LARS1 | |
| SCHEMBL3097275 | 0.90 | MMP8 (0.51) | ALDH1A1MMP13LARS1PPARGPPARD | |
| SCHEMBL3088714 | 0.89 | KDM4E (0.58) | ALDH1A1KDM4EKMT2ARAPGEF3MMP1 | |
| SCHEMBL3092800 | 0.88 | KAT6A (0.49) | ALDH1A1KDM4EKMT2ARAPGEF3MMP1 | |
| SCHEMBL3097004 | 0.88 | LARS1 (0.50) | ALDH1A1KMT2ARAPGEF3LARS1MMP8 | |
| SCHEMBL3085503 | 0.87 | LARS1 (0.47) | ALDH1A1KMT2ARAPGEF3LARS1MMP8 | |
| SCHEMBL3103795 | 0.87 | LARS1 (0.47) | ALDH1A1LARS1PPARGPPARDPPARA | |
| SCHEMBL14999939 | 0.86 | ALDH1A1 (0.52) | ALDH1A1KDM4EKMT2ARAPGEF3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | ALDH1A1 617/4885KDM4E 3644/4885KMT2A 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.